Eli Lilly and Company (LLY)
After hours:
| Previous close | 787.02 |
| Open | 784.71 |
| Bid | 770.20 x 1200 |
| Ask | 771.35 x 1300 |
| Day's range | 770.20 - 786.14 |
| 52-week range | 419.80 - 800.78 |
| Volume | |
| Avg. volume | 2,818,903 |
| Market cap | 732.876B |
| Beta (5Y monthly) | 0.37 |
| PE ratio (TTM) | 113.90 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 5.20 (0.66%) |
| Ex-dividend date | 15 May 2024 |
| 1y target est | N/A |
- PR Newswire
With Once-a-Week Dosing, Insulin Efsitora Alfa Delivers A1C Reduction and Safety Profile Consistent with Daily Insulin
Eli Lilly and Company (NYSE: LLY) today announced positive topline results from the QWINT-2 and QWINT-4 phase 3 clinical trials evaluating once-weekly insulin efsitora alfa (efsitora) in adults with type 2 diabetes using insulin for the first time (insulin naïve) and those who require multiple daily insulin injections. In the treat-to-target clinical trials, efsitora showed non-inferior A1C reduction compared to the most commonly used daily basal insulins globally.
- PR Newswire
Alonzo Weems to Retire as Executive Vice President of Enterprise Risk Management and Chief Ethics and Compliance Officer
Eli Lilly and Company (NYSE: LLY) today announced that Alonzo Weems, executive vice president of enterprise risk management and chief ethics and compliance officer, and a member of Lilly's Executive Committee, will retire after 27 years of service with the company, effective Dec. 31, 2024. Weems will continue to serve in his role while the company conducts an internal and external search for a chief ethics and compliance officer.
- PR Newswire
Lilly Declares Second-Quarter 2024 Dividend
The board of directors of Eli Lilly and Company (NYSE: LLY) has declared a dividend for the second quarter of 2024 of $1.30 per share on outstanding common stock.
